ViaCyte

@ViaCyte

ViaCyte is a regenerative medicine company dedicated to developing a functional cure for type 1 diabetes.

San Diego
Vrijeme pridruživanja: prosinac 2014.

Tweetovi

Blokirali ste korisnika/cu @ViaCyte

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ViaCyte

  1. 13. sij

    Don't forget our presentation is at 11:15 am PST today in Franciscan C (Ballroom Level).

    Poništi
  2. 8. sij
    Poništi
  3. 24. pro 2019.

    ViaCyte wishes you a very happy holiday! Thank you for following our progress in developing a functional cure for insulin-requiring .

    Poništi
  4. 24. pro 2019.

    ViaCyte wishes you a very happy holiday! Thank you for following our progress in developing a functional cure for insulin-requiring .

    Poništi
  5. 16. pro 2019.

    Join the ViaCyte team: We are seeking a Manufacturing Technician, Executive Administrative Assistant, Facilities Mechanic, Associate Quality Control, and HR Specialist

    Poništi
  6. 28. stu 2019.

    Happy Thanksgiving from ViaCyte! We are thankful for your support and for our team and collaborators who are dedicated to curing type 1 diabetes.

    Poništi
  7. 5. stu 2019.

    Tomorrow at 2 pm: ViaCyte’s VP, Research and CSO Kevin D’Amour to present at session for “From Stem Cell Biology to New Therapies”

    Poništi
  8. 4. stu 2019.

    Nov. 6: ViaCyte VP, Research and CSO Kevin D’Amour to speak at ’s “From Stem Cell Biology to New Therapies”

    Poništi
  9. 3. lis 2019.

    For more on the new ViaCyte clinical data, see the live webcast from the Cell & Gene Meeting on the Mesa today at 1:45 pm:

    Poništi
  10. 3. lis 2019.

    ViaCyte presents preliminary PEC-Direct clinical data showing implanted cells, when effectively engrafted, are capable of producing circulating C-peptide, a biomarker for insulin, in patients with type 1 :

    Poništi
  11. 1. lis 2019.

    ViaCyte CEO and President Paul Laikind to present at 1:45 pm PT at the Cell & Gene Meeting on the Mesa:

    Poništi
  12. 26. ruj 2019.

    ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more w/

    Poništi
  13. 17. ruj 2019.

    News: and ViaCyte present positive in vitro data towards a potential immune-evasive cell replacement therapy for at :

    Poništi
  14. 9. ruj 2019.

    Thanks for a great visit! It was great to share our progress in developing a functional cure for insulin-requiring and to learn about your legislative priorities to support in .

    Poništi
  15. 24. srp 2019.
    Poništi
  16. 27. lip 2019.
    Poništi
  17. 30. svi 2019.

    Thank you to the editors and local experts who named ViaCyte and Gene Yeo the 2019 “Big Idea” winners!

    Poništi
  18. proslijedio/la je Tweet
    29. svi 2019.

    And the Big Idea Award winners are… Gene Yeo of and !

    Poništi
  19. 22. svi 2019.

    A great round up of how ViaCyte’s breakthrough science, products and collaborations have earned the company a spot in ’s 2019 Awards, “Big Idea” category

    Poništi
  20. 8. svi 2019.

    New Event May 13 11AM ET/8AM PT: Join ViaCyte VP Dr. Howard Foyt and for a webinar on “State-of-the-Art Technology for Insulin Therapy in Type 1 : Engineering and Cell-based Approaches”

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·